Poseida Therapeutics Acquisition Set to Be Completed, Roche Says
MT Newswires Live
Jan 08, 2025
Roche said Wednesday that it has accepted nearly 65 million shares of Poseida Therapeutics (PSTX), or about 66% of the company's stock, and that it intends to complete its acquisition of the biopharmaceutical company.
The shares had been tendered at a price of $9 per share in cash, plus a contingent value right of up to $4 per share. Roche said in November that it agreed to acquire Poseida in a deal worth up to $1.5 billion.
Following completion, Poseida will become a wholly owned subsidiary of Roche, and its shares will cease to be traded on Nasdaq, Roche said.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.